BioCentury
ARTICLE | Company News

BioVersys AG, GlaxoSmithKline, Wellcome Trust deal

June 9, 2014 7:00 AM UTC

BioVersys and GlaxoSmithKline partnered to develop a preclinical compound and two backup compounds to treat tuberculosis (TB). BioVersys has been developing the compounds, which are designed to improve the efficacy of existing TB drug ethionamide, since 2013 with a consortium that includes the University of Lille (Villeneuve-d'Ascq, France), Institut National de la Sante et de la Recherche Medicale (INSERM) and Centre National de la Recherche Scientifique (CNRS).

The partners will use BioVersys' transcriptional regulator inhibitory compound (TRIC) technology. BioVersys said GSK will focus on in vivo work using mouse models and ADMET, while BioVersys and the university will focus on biochemical and in vitro assays. BioVersys said newly generated IP will be jointly owned by BioVersys and GSK. ...